Lana Pine

The presence of mental health, pain-related illnesses, and metabolic diseases were significantly associated with the worsening of arthritis-related pain, severity, and disease activity.

Angus Worthing, MD, discusses the recent developments in rheumatology and his predictions for the future of treatment moving into 2024 and beyond.

Findings shed light on the potential significance of recognizing and managing type D personality traits in the context of fibromyalgia care.

Proactive disease management could result in more positive emotional and mental experiences in patients with gout.

After adjusting for confounders, data revealed higher levels of obesity indices were linked with a gradual and dose-dependent increase in urate levels.

Findings revealed an elevation of educational attainment by one standard deviation exhibited a protective effect against gout.

Thematic analysis revealed common themes, including uncertainty about the cause of fibromyalgia, feelings of invisibility, confusion about symptoms and flares, and a strong desire for more accessible treatment information.

On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.

Gout incidence rate significantly increased after relieving urinary tract obstruction.

Wesley Mizutani, MD, discusses California's SB 496 legislation, which addresses the crucial role of biomarkers in guiding optimal drug selection to improve overall healthcare outcomes.

There were no differences in patient-rated pain scores, time to flare resolution, and the risk of recurrent flare in patients initiating urate-lowering therapy during treatment and those delaying treatment.

Roger A Levy, MD, PhD, discusses the transformative impact of the KDIGO guidelines, which recommend early initiation of belimumab for lupus nephritis.

Roger A Levy, MD, PhD, discusses the recent guideline updates regarding the treatment and management of lupus nephritis.

A significantly larger proportion of patients receiving the biosimilar QL0911 achieved a durable platelet response when compared with placebo.

Results showed no differences regarding safety, although the biosimilar group had slightly more discontinuations due to inefficacy.

Improvements in insulin resistance were reported in patients with RA and type 2 diabetes treated with tofacitinib.

Test your knowledge of treatment persistence, adherence, and switching patterns of adalimumab biosimilar ABP 501 between adalimumab-naïve patients and adalimumab-experienced patients.

The FDA has extended the shelf-life of 4 mg naloxone hydrochloride nasal spray (Narcan) for nonprescription over-the-counter use from 3 years to 4 years.

Benign prostatic hyperplasia was 1.13-fold higher in those with gout when compared with controls.

Patients with gout had a 1.26-fold higher likelihood of experiencing migraines when compared with those without gout.

A study compared the efficacy of febuxostat and benzbromarone in treating gout, emphasizing the lack of consensus in previous research and the need for future, well-designed studies.

During a 10-year period, estimated access to drugs increased among Polish patients with rheumatic and musculoskeletal diseases.

Compared to routine care, TCMD could better reduce the incidence of adverse events and the level of laboratory indicators.

Significant differences in the practice of primary healthcare physicians were observed based on medical specialty when treating and managing asymptomatic hyperuricemia and gout.

Only 10% of providers surveyed follow the American College of Rheumatology criteria for fibromyalgia.

Entering menopause prior to age 45 was associated with a 46% increased risk of developing RA compared with those who began menopause at ≥50 years.

Investigators evaluated employment rates at various disease stages of rheumatoid arthritis (RA) to uncover the key predictors influencing work among this patient population. Test your knowledge of employment and RA with this quiz.

Results indicate the potential relevance of pressure pain thresholds for understanding the mechanisms that contribute to pain in fibromyalgia.

Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.

Results indicated patients with GERD are at a 69% increased risk of developing RA.